SG155257A1 - Methods of diagnosing and treating complications of pregnancy - Google Patents

Methods of diagnosing and treating complications of pregnancy

Info

Publication number
SG155257A1
SG155257A1 SG200905831-4A SG2009058314A SG155257A1 SG 155257 A1 SG155257 A1 SG 155257A1 SG 2009058314 A SG2009058314 A SG 2009058314A SG 155257 A1 SG155257 A1 SG 155257A1
Authority
SG
Singapore
Prior art keywords
methods
diagnosing
pregnancy
treating complications
pregnancy related
Prior art date
Application number
SG200905831-4A
Other languages
English (en)
Inventor
S Ananth Karumanchi
Vikas Sukhatme
Original Assignee
Beth Israel Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Hospital filed Critical Beth Israel Hospital
Publication of SG155257A1 publication Critical patent/SG155257A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Reproductive Health (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
SG200905831-4A 2004-09-24 2005-09-26 Methods of diagnosing and treating complications of pregnancy SG155257A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US61317004P 2004-09-24 2004-09-24

Publications (1)

Publication Number Publication Date
SG155257A1 true SG155257A1 (en) 2009-09-30

Family

ID=36090722

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200905831-4A SG155257A1 (en) 2004-09-24 2005-09-26 Methods of diagnosing and treating complications of pregnancy

Country Status (16)

Country Link
US (3) US20060067937A1 (fr)
EP (2) EP2347765B1 (fr)
JP (3) JP5270161B2 (fr)
KR (2) KR20130119506A (fr)
CN (1) CN101065667B (fr)
AT (1) ATE488251T1 (fr)
AU (1) AU2005286626B2 (fr)
BR (1) BRPI0515884A (fr)
CA (1) CA2581336C (fr)
DE (1) DE602005024850D1 (fr)
DK (1) DK1804836T3 (fr)
HK (2) HK1107592A1 (fr)
MX (1) MX2007003522A (fr)
NI (1) NI200700081A (fr)
SG (1) SG155257A1 (fr)
WO (1) WO2006034507A2 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1804836T3 (da) 2004-09-24 2011-01-24 Beth Israel Hospital Fremgangsmåder til diagnosticering og behandling af graviditetskomplikationer
US7740849B2 (en) * 2004-09-24 2010-06-22 Beth Israel Deaconess Medical Center Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders
DE602005023216D1 (de) 2004-12-15 2010-10-07 Beth Israel Hospital Nukleinsäuren und polypeptide zur diagnose und behandlung von schwangerschaftskomplikationen
EP1866441A4 (fr) * 2005-03-24 2009-11-11 Beth Israel Hospital Procédés de diagnostic de la trisomie foetale 13 ou d'un risque de trisomie foetale 13 pendant la grossesse
US20090170767A1 (en) * 2006-05-31 2009-07-02 Beth Israel Deaconess Medical Center Soluble Endoglin Compounds for the Treatment and Prevention of Cancer
US20090286271A1 (en) * 2006-05-31 2009-11-19 Karumanchi Ananth S Methods of Diagnosing and Treating Complications of Pregnancy
WO2008030283A1 (fr) * 2006-05-31 2008-03-13 Beth Israel Deaconess Medical Center Méthodes pour le diagnostic et le traitement de complications associées à une grossesse
US20080071151A1 (en) * 2006-06-30 2008-03-20 Sogin David C Method and Apparatus for Diagnosing Pre-eclampsia
EP1936380A1 (fr) * 2006-12-21 2008-06-25 F. Hoffmann-Roche AG Facteur de croissance placentaire, FLT1 soluble et endogline en tant que prédicateurs de l'état angiogénique d'un sujet
GB0703683D0 (en) * 2007-02-26 2007-04-04 Ark Therapeutics Ltd The treatment of complications in pregnancy
US20100016173A1 (en) * 2008-01-30 2010-01-21 Proteogenix, Inc. Maternal serum biomarkers for detection of pre-eclampsia
WO2009144229A1 (fr) * 2008-05-27 2009-12-03 F. Hoffmann-La Roche Ag Procédé de réduction de risque dans un contrôle glycémique
WO2010122231A1 (fr) * 2009-04-23 2010-10-28 Wallac Oy Procédés de détermination des risques de santé de la femme enceinte
CA2799227C (fr) 2010-05-14 2020-06-16 Beth Israel Deaconess Medical Center, Inc. Dispositifs extracorporels et procedes de traitement de complications de grossesse
US9592331B2 (en) 2011-02-07 2017-03-14 Aggamin Llc Methods and systems for treating eclampsia or pre-eclampsia
US20140127703A1 (en) 2011-06-28 2014-05-08 Vitateq Biotechnology Gmbh Method for Diagnosing Preeclampsia
CN104011069A (zh) 2011-08-01 2014-08-27 塔夫茨医学中心有限公司 心力衰竭及相关病症的治疗
JP6034394B2 (ja) * 2011-11-09 2016-11-30 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 切迫妊娠高血圧腎症および／またはＨＥＬＬＰ症候群の指標としてのｓＦｌｔ−１またはエンドグリン／ＰｌＧＦ比の動態
EP3182126A3 (fr) * 2012-06-15 2017-08-02 Wayne State University Biomarqueurs utilisés pour prédire ou détecter précocement la pré?éclampsie et/ou le syndrome de hellp
EP2706359A1 (fr) 2012-09-07 2014-03-12 Roche Diagniostics GmbH Supports et procédés pour appliquer le taux sFlt-1 ou endogline/PlGF pour éliminer l'apparition de la toxémie prééclamptique dans une certaine période
MX356775B (es) * 2012-06-27 2018-06-13 Hoffmann La Roche Medios y metodos que aplican sflt-1/plgf o relacion de endoglina/plgf para descartar el inicio de preeclampsia en un determinado periodo de tiempo.
JP2015522258A (ja) * 2012-09-10 2015-08-06 ウェーン ステイト ユニヴァーシティＷａｙｎｅ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ 子癇前症及び／またはｈｅｌｌｐ症候群の予測または早期検出のバイオマーカー検査
US20150330989A1 (en) * 2012-11-15 2015-11-19 The Brigham And Women's Hospital, Inc. Method and system for diagnosing and treating preeclampsia
KR102241051B1 (ko) 2013-02-28 2021-04-16 더 차이니즈 유니버시티 오브 홍콩 대량 동시 rna 서열분석에 의한 모체 혈장 전사물 분석
JP6519842B2 (ja) * 2013-10-04 2019-05-29 国立大学法人神戸大学 福山型筋ジストロフィー治療用アンチセンス核酸
CA2963968C (fr) * 2014-10-10 2024-01-09 Wayne State University Procedes et compositions concernant des dosages de cellules trophoblastiques extra-villeux d'origine foetale
RU2607029C1 (ru) * 2015-10-20 2017-01-10 ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ "РОССИЙСКИЙ НАУЧНЫЙ ЦЕНТР РАДИОЛОГИИ И ХИРУРГИЧЕСКИХ ТЕХНОЛОГИЙ" МИНИСТЕРСТВА ЗДРАВООХРАНЕНИЯ РОССИЙСКОЙ ФЕДЕРАЦИИ / ФГБУ "РНЦРХТ" Минздрава России ШТАММ ГИБРИДНЫХ КУЛЬТИВИРУЕМЫХ КЛЕТОК ЖИВОТНЫХ Mus musculus L. - EN-4C9 - ПРОДУЦЕНТ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ ПРОТИВ ЭНДОГЛИНА (CD105) ЧЕЛОВЕКА
US20190128895A1 (en) * 2016-04-20 2019-05-02 Ldx Prognostics Limited Co. Methods and compositions for prognosing preterm birth
WO2017197573A1 (fr) 2016-05-17 2017-11-23 Ldx Prognostics Limited Co. Méthodes et compositions pour fournir une évaluation de la prééclampsie
AU2018331400A1 (en) 2017-09-13 2020-04-02 Progenity, Inc. Preeclampsia biomarkers and related systems and methods
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
KR20200128676A (ko) * 2018-02-06 2020-11-16 아미쿠스 세라퓨틱스, 인코포레이티드 임신 환자의 파브리병 치료를 위한 미갈라스타트의 용도
KR20220009955A (ko) 2019-04-17 2022-01-25 컴퍼스 패쓰파인더 리미티드 실로시빈에 의한 우울증 및 기타 다양한 장애의 치료
EP4070113A4 (fr) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. Évaluation de la prééclampsie à l'aide de dosages du facteur de croissance placentaire libre et dissocié
US20230030032A1 (en) * 2019-12-13 2023-02-02 Aggamin, LLC Methods and systems for treating or preventing pregnancy-related hypertensive disorders
US20230056992A1 (en) * 2019-12-13 2023-02-23 Aggamin, LLC Methods and systems for treating or preventing pregnancy-related hypertensive disorders
EP3900733A1 (fr) 2020-04-24 2021-10-27 Derma Innovate S.L. Activateurs de la kinase src et inhibiteurs de fonction eng comme stimulateurs de l'homéostasie cutanée/régénération et de la croissance des cheveux
CN115873943B (zh) * 2023-02-13 2024-03-29 山东大学 骨形态发生蛋白2在子痫前期诊断、预防和治疗中的应用

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
IL89489A0 (en) 1988-03-09 1989-09-10 Hybritech Inc Chimeric antibodies directed against human carcinoembryonic antigen
WO1989009622A1 (fr) 1988-04-15 1989-10-19 Protein Design Labs, Inc. Anticorps chimeriques specifiques au recepteur il-2
ATE119198T1 (de) 1988-04-16 1995-03-15 Celltech Ltd Verfahren zur herstellung von proteinen mittels rekombinanter dna.
US5240848A (en) 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
US5238819A (en) * 1988-12-14 1993-08-24 The Regents Of The University Of California Diagnostic assay for the detection of preeclampsia
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US5219739A (en) 1989-07-27 1993-06-15 Scios Nova Inc. DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121
US5194596A (en) 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
DE69233254T2 (de) 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanisierter Heregulin Antikörper
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
US5660827A (en) * 1992-03-05 1997-08-26 Board Of Regents, The University Of Texas System Antibodies that bind to endoglin
WO1993021319A1 (fr) 1992-04-08 1993-10-28 Cetus Oncology Corporation ANTICORPS HUMANISES SPECIFIES PAR C-erbB-2
US5830847A (en) 1992-10-30 1998-11-03 Hsc Research & Development Limited Partnership Soluble TGF-β-binding endoglin polypeptides and homodimers
US5712395A (en) * 1992-11-13 1998-01-27 Yissum Research Development Corp. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5763441A (en) * 1992-11-13 1998-06-09 Sugen, Inc. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5895783A (en) 1993-07-16 1999-04-20 Schering Aktiengesellschaft Treatment of preeclampsia and preterm labor with combination of progestational agent and a nitric oxide synthase substrate and/or donor
US6410322B1 (en) 1993-07-27 2002-06-25 Hybridon Inc Antisense oligonucleotide inhibition of vascular endothelial growth factor expression
US5504074A (en) 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US5861499A (en) 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
JPH10501681A (ja) 1994-02-22 1998-02-17 ダナ−ファーバー キャンサー インスティチュート 核酸送達システムならびにその合成および使用方法
US5543138A (en) * 1994-03-10 1996-08-06 Genetics Institute, Inc. Methods of diagnosing and treating preeclampsia
CA2190268C (fr) 1994-05-13 2000-01-25 Wolfgang Bohm Colonne sterile et apyrogene couplee a une proteine en vue de la fixation et de l'extraction de substances donnees du sang
US5641636A (en) * 1994-05-20 1997-06-24 University Of Pennsylvania Method of predicting fetal membrane rupture based on matrix metalloproteinase-9 activity
US6613757B1 (en) 1994-09-22 2003-09-02 Board Of Regents, The University Of Texas System Combination of prostacyclin with an estrogen or progestin for the prevention and treatment of atherosclerotic vascular disease including preeclampsia and for the treatment of hypertension, and for hormone replacement therapy
US5989811A (en) * 1994-09-29 1999-11-23 Urocor, Inc. Sextant core biopsy predictive mechanism for non-organ confined disease status
WO1996016975A1 (fr) 1994-11-29 1996-06-06 Duke University Diagnostic et therapie concernant l'angiomatose hemorragique familiale
IT1271593B (it) 1994-11-30 1997-06-04 Sanitaria Scaligera Spa Procedimento ed apparecchiatura per l'immunoadsorbimento specifico di virus hiv, di antigene gp120 e complesso cd4-gp120.
GB9512994D0 (en) * 1995-06-26 1995-08-30 Brf International Method for quantitative measurement of an enzyme linked immunosorbent assay
US5830879A (en) 1995-10-02 1998-11-03 St. Elizabeth's Medical Center Of Boston, Inc. Treatment of vascular injury using vascular endothelial growth factor
US5750345A (en) * 1995-10-31 1998-05-12 Evanston Hospital Corporation Detection of human α-thalassemia mutations and their use as predictors of blood-related disorders
US5910482A (en) * 1996-03-19 1999-06-08 Board Of Regents, The University Of Texas System Treatment or prevention of preeclampsia, eclampsia with calcitonin gene related peptide, CGRP analog, progestational agent, nitric oxide source, and cyclooxygenase inhibitor
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6399585B1 (en) * 1996-05-15 2002-06-04 Janet E. Larson In Utero treatment of CFTR-related deficiencies
ES2169864T3 (es) * 1996-05-31 2002-07-16 Health Research Inc Anticuerpos monoclonales anti-endoglina y su uso en terapia anti-angiogenesis.
GB9618931D0 (en) * 1996-09-11 1996-10-23 Univ London Inositol phosphoglycans for therapeutic use in pre-eclampsia and diabetes
EP0951298A1 (fr) 1996-12-23 1999-10-27 Cambridge University Technical Services Limited Diagnostic et traitement de grossesses pathologiques
CA2283356C (fr) * 1997-03-07 2009-06-30 Mount Sinai Hospital Methodes de diagnostic d'une regulation necessaire de l'invasion trophoblastique
US20020031513A1 (en) * 1997-11-24 2002-03-14 Shamir Leibovitz Method and pharmaceutical composition for inhibiting premature rapture of fetal membranes, ripening of uterine cervix and preterm labor in mammals
US20010056068A1 (en) 1998-03-04 2001-12-27 Kristof Chwalisz Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives
US20030114407A1 (en) 2001-12-06 2003-06-19 Monia Brett P. Antisense modulation of G protein-coupled receptor ETBR-LP-2 expression
US6677300B1 (en) * 1998-09-09 2004-01-13 Scios, Inc. Treatment of microvascular angiopathies
US7030083B2 (en) * 1998-09-09 2006-04-18 University Of Washington Treatment of eclampsia and preeclampsia
US6245577B1 (en) * 1998-09-11 2001-06-12 Midland Bioproducts Corporation IgG antibody testing method
EP1016726A1 (fr) 1998-12-30 2000-07-05 Introgene B.V. Thérapie génique pour la promotion de l' angiogenèse
CA2369764A1 (fr) * 1999-04-16 2000-10-26 Yale University Mutations enos utiles en therapie genique et pour le criblage d'agents therapeutiques
PT2796553T (pt) 2000-03-30 2019-09-27 Massachusetts Inst Technology Mediadores de interferência de arn específicos de sequência de arn
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
AR031129A1 (es) * 2000-09-15 2003-09-10 Pharmacia Corp Derivados de los acidos 2-amino-2-alquil-4-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa
GB0026823D0 (en) * 2000-11-02 2000-12-20 King S College London Diagnosis of pre-eclampsia
WO2002070535A1 (fr) 2001-03-01 2002-09-12 Isis Pharmaceuticals, Inc. Modulation antisens de l'expression de recql5
US7713705B2 (en) * 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
WO2002086497A2 (fr) * 2001-04-24 2002-10-31 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Utilisation du facteur 2alpha induit par l'hypoxie pour le traitement du syndrome de detresse respiratoire du nouveau-ne et comme cible pour le traitement de l'hypertension pulmonaire
CA2496253C (fr) * 2002-07-19 2016-05-10 Beth Israel Deaconess Medical Center, Inc. Procedes de diagnostic et de traitement de pre-eclampsie ou d'eclampsie
US7435419B2 (en) * 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
US7335362B2 (en) * 2002-07-19 2008-02-26 Beth Israel Deaconess Medical Center Methods of treating pre-eclampsia or eclampsia
DE10333105B3 (de) 2003-07-21 2005-05-25 OCé PRINTING SYSTEMS GMBH Einrichtung zur Einstellung der Spannung einer Materialbahn, die durch eine die Materialbahn bearbeitende Prozessstation bewegt wird
EP1664797B1 (fr) * 2003-09-23 2015-11-11 The General Hospital Corporation Criblage destine a pré-éclampsie
US20050181451A1 (en) 2004-02-12 2005-08-18 Bates Harold M. Detection of asymptomatic coronary artery disease using atherogenic proteins and acute phase reactants
DK1804836T3 (da) 2004-09-24 2011-01-24 Beth Israel Hospital Fremgangsmåder til diagnosticering og behandling af graviditetskomplikationer
US7740849B2 (en) * 2004-09-24 2010-06-22 Beth Israel Deaconess Medical Center Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders
DE602005023216D1 (de) 2004-12-15 2010-10-07 Beth Israel Hospital Nukleinsäuren und polypeptide zur diagnose und behandlung von schwangerschaftskomplikationen
EP1839056B1 (fr) * 2004-12-21 2011-08-03 Yale University Diagnostic de la preeclampsie
WO2008030283A1 (fr) 2006-05-31 2008-03-13 Beth Israel Deaconess Medical Center Méthodes pour le diagnostic et le traitement de complications associées à une grossesse
US20100247650A1 (en) 2009-03-31 2010-09-30 Smith Henry J Treatment for pre-eclampsia in pregnant women using targeted apheresis

Also Published As

Publication number Publication date
HK1107592A1 (en) 2008-04-11
WO2006034507A3 (fr) 2007-06-14
KR20130119506A (ko) 2013-10-31
MX2007003522A (es) 2007-06-11
KR20070059174A (ko) 2007-06-11
ATE488251T1 (de) 2010-12-15
WO2006034507A2 (fr) 2006-03-30
CA2581336A1 (fr) 2006-03-30
DK1804836T3 (da) 2011-01-24
EP2347765A1 (fr) 2011-07-27
AU2005286626B2 (en) 2012-11-08
JP5270161B2 (ja) 2013-08-21
EP1804836B1 (fr) 2010-11-17
AU2005286626A1 (en) 2006-03-30
CN101065667B (zh) 2013-09-04
US10413591B2 (en) 2019-09-17
DE602005024850D1 (de) 2010-12-30
KR101356894B1 (ko) 2014-02-06
JP2012211131A (ja) 2012-11-01
JP2008514631A (ja) 2008-05-08
US20060067937A1 (en) 2006-03-30
BRPI0515884A (pt) 2008-08-12
NI200700081A (es) 2008-05-13
EP1804836A2 (fr) 2007-07-11
CA2581336C (fr) 2022-10-04
EP2347765B1 (fr) 2014-01-22
CN101065667A (zh) 2007-10-31
US20170072018A1 (en) 2017-03-16
US20110243956A1 (en) 2011-10-06
JP5715589B2 (ja) 2015-05-07
EP1804836A4 (fr) 2008-07-09
JP2015057426A (ja) 2015-03-26
HK1160388A1 (en) 2012-08-17

Similar Documents

Publication Publication Date Title
SG155257A1 (en) Methods of diagnosing and treating complications of pregnancy
MX2008015197A (es) Metodos de diagnosticar y tratar las complicaciones del embrazo.
WO2005113000A3 (fr) Activité anticancéreuse d'un anticorps monoclonal anti-thymidine kinase
WO2007110678A3 (fr) Anticorps neutralisants et procédés d'utilisation
WO2010031056A3 (fr) Procédés et compositions pour moduler l'activité ire1, src, et abl
WO2006133148A3 (fr) Methode de production d'anticorps presentant une fonction amelioree
SG10201407388XA (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
MX2009004532A (es) Composiciones y metodos para unir esfingosina-1-fosfato.
WO2005084109A3 (fr) Gène mh15 spécifique de cancer
WO2005080431A3 (fr) Anticorps monoclonaux bloquant specifiquement l'activite biologique d'un antigene tumoral
WO2005077007A3 (fr) Methodes de diagnostic et de traitement de la preeclampsie ou de l'eclampsie
WO2006113242A3 (fr) Procede d'augmentation de la testosterone et concentrations steroidiennes correspondantes chez la femme
UA97946C2 (ru) Моноклональное антитело, специфически связывающееся с внеклеточным доменом ilt7 человека
WO2006009836A3 (fr) Composes associes au facteur de differenciation tissulaire et leurs analogues
WO2007120689A3 (fr) Procédés d'utilisation du récepteur gpr119 pour identifier des composés utiles pour augmenter la masse osseuse chez un individu
SG155931A1 (en) Wnt proteins and detection and treatment of cancer
TW200518755A (en) Selective erbB2 inhibitor/anti-erbB antibody combinations in the treatment of cancer
WO2006001931A3 (fr) Prouroguanyline, analogues synthetiques ou produits de clivage proteolytiques derives de celle-ci servant d'agents therapeutiques ou diagnostiques pour des maladies impliquant une homeostasie de sel et/ou d'eau
WO2007028088A3 (fr) Methodes d'amelioration de la capacite de deshydratation de boue avec un traitement d'alpha-amylase
WO2007120787A3 (fr) Procede de traitement, de diagnostic ou de detection du cancer
WO2007134028A3 (fr) Biomarqueurs pour la dépression et méthodes d'utilisation de ceux-ci
WO2005072290A3 (fr) Methodes de traitement, de diminution ou de prevention d'etats auto-immuns
WO2006029220A3 (fr) Therapie combinee utilisant des anticorps anti-ctla4 et anti-4-1bb
WO2006086772A3 (fr) Procede de diagnostic et de traitement du cancer au moyen de variants d'epissure de $g(b)-catenine
PL1711531T3 (pl) Przeciwciała neutralizujące przeciwko TLR4/MD-2 oraz sposoby ich zastosowania